Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL

Jefferies Financial Group Inc. acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 126,565 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,429,000. Jefferies Financial Group Inc. owned approximately 0.40% of Collegium Pharmaceutical as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth $334,000. Quantbot Technologies LP boosted its position in shares of Collegium Pharmaceutical by 380.2% in the 3rd quarter. Quantbot Technologies LP now owns 51,236 shares of the specialty pharmaceutical company’s stock valued at $1,793,000 after purchasing an additional 40,567 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 43.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,563 shares of the specialty pharmaceutical company’s stock valued at $125,000 after purchasing an additional 1,079 shares during the period. Hillsdale Investment Management Inc. increased its stake in Collegium Pharmaceutical by 14.1% in the 3rd quarter. Hillsdale Investment Management Inc. now owns 203,000 shares of the specialty pharmaceutical company’s stock worth $7,103,000 after purchasing an additional 25,100 shares in the last quarter. Finally, NewEdge Wealth LLC increased its stake in Collegium Pharmaceutical by 24.2% in the 3rd quarter. NewEdge Wealth LLC now owns 21,779 shares of the specialty pharmaceutical company’s stock worth $781,000 after purchasing an additional 4,237 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on COLL shares. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday. Barclays cut their price target on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Finally, Needham & Company LLC reduced their price target on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Collegium Pharmaceutical Stock Down 0.1%

NASDAQ:COLL opened at $37.27 on Tuesday. The business’s fifty day moving average price is $45.24 and its 200 day moving average price is $42.12. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of 21.80 and a beta of 0.67. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The business had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. During the same quarter in the previous year, the business posted $1.77 earnings per share. The company’s revenue was up 12.9% compared to the same quarter last year. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. This trade represents a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.51% of the stock is owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.